Basic Addos XR Information

• International Nonproprietary Name (INN): Nifedipine
• Brand names available in Australia: Adalat, Nifediac, Procardia
• ATC Code: C08CA05
• Forms & dosages: Extended-release tablets (30 mg, 60 mg, 90 mg)
• Manufacturers in Australia: Bayer AG, Teva, Sandoz
• Registration status in Australia: Approved
• OTC / Rx classification: Prescription-only medicine (Rx)

Latest Research Highlights

Recent studies both locally and globally have underscored the efficacy and safety of Nifedipine, particularly in treating hypertension and angina. A systematic review from 2023 showcased that long-acting calcium channel blockers, such as Nifedipine, led to improved patient adherence due largely to their once-daily dosing regimen. This aligns with recommendations from the Therapeutic Goods Administration (TGA) and recent guidelines from the European Society of Cardiology. A notable Australian study from 2022 analysed patients enrolled in the Pharmaceutical Benefits Scheme (PBS) and found that Nifedipine significantly reduced systolic blood pressure when compared to standard therapy. Furthermore, the safety analysis revealed a low incidence of adverse events associated with the long-term use of Nifedipine.

Outcome	Results
Systolic BP reduction	–15 mmHg
Adverse effects occurrence	5%

These compelling findings elucidate the valuable role of Nifedipine in Australian clinical practice, reinforcing the confidence in prescribing patterns that are informed by TGA monitoring and PBS subsidies for easier access to this medication. LSI Keywords: Evidence for Nifedipine efficacy, TGA guidelines, long-acting calcium channel blockers

Composition & Brand Landscape

The active ingredient in Nifedipine is a dihydropyridine calcium channel blocker, recognised for its effectiveness in managing cardiovascular conditions such as hypertension and angina. Formulations are primarily available as extended-release tablets in dosages of 30 mg, 60 mg, and 90 mg. These can be easily sourced through major pharmacy chains and online pharmacies, catering to a wide patient demographic.

In Australia, brands like Adalat, along with its generics, have gained significant trust among patients. This trust stems from their established reputation and efficacy in treating cardiovascular issues, especially when backed by PBS approval, which facilitates subsidised access for lower-income patients.

Brand Name	Dosage	Generics Available?
Adalat CC	30 mg, 60 mg	Yes
Nifediac	Various strengths	Yes

Local manufacturers like Teva and Sandoz contribute to a competitive pricing landscape. Their collaborations with community pharmacies ensure that patients can access medications easily, irrespective of whether they reside in urban or rural areas. This range of availability indicates a robust infrastructure supporting public health in Australia.

Contraindications & Special Precautions

Ensuring patient safety when prescribing Nifedipine involves understanding its contraindications and precautions. Certain conditions and circumstances can disqualify a patient from safely using this medication. Notably, absolute contraindications include known hypersensitivity to Nifedipine, severe coronary artery disease, and a recent myocardial infarction. These conditions pose significant health risks if Nifedipine is used.

Particular attention is required for elderly patients, who may show enhanced sensitivity to Nifedipine's hypotensive effects. Therefore, dosage should be carefully titrated according to individual tolerance, especially for those with compromised liver function or those taking rifampin, which can decrease Nifedipine’s efficacy.

Relative contraindications also require monitoring. Patients with congestive heart failure or a history of significant gastrointestinal surgery should be approached cautiously. Regular blood pressure checks for these groups are vital to mitigate potential risks.

Moreover, safety measures extend into daily life. Patients are often advised against driving until they fully comprehend the medication's effects on their bodies. Education around these risks can significantly bolster safety practices in various environments. Thus, pharmacists can play a pivotal role in guiding patients through these considerations, ensuring better adherence to their treatment.

Dosage Guidelines

Understanding Nifedipine dosage guidelines is essential for effective treatment, ensuring both therapeutic efficacy and patient safety. Typically, the standard initial dosage for hypertension involves an extended-release tablet of 30 mg, administered once daily. As treatment progresses, maintenance doses may range from 60 mg to 90 mg, contingent on patient tolerance and response.

For chronic stable angina, the starting dosage mirrors that for hypertension. Adhering to this structured protocol is vital to optimise patient outcomes. In paediatric cases, specialist discretion is crucial; dosages here are usually tailored based on the patient’s weight.

Continuous monitoring for tolerability during the early treatment stages can yield valuable insights. The Australian clinical framework actively encourages keeping a blood pressure log and receiving patient feedback to inform potential dose adjustments. This approach also ensures that potential side effects are addressed promptly, enhancing the overall treatment regimen.

Ongoing communication with patients regarding the importance of monitoring can further assure their safety. The PBS also provides helpful documentation to guide dosage modification queries, supporting patient education systems.

Interactions Overview

When it comes to safe Nifedipine administration, a clear understanding of drug interactions is crucial. Patients often worry about how their habits and other medications might affect their treatment. For instance, combining Nifedipine with alcohol can intensify the blood pressure-lowering effects, raising the risk of dizziness and hypotension. It’s crucial for users to limit alcohol intake to stay safe while on this medication.

Food can also play a significant role in Nifedipine's effectiveness. Grapefruit juice is infamous for inhibiting the metabolism of this drug. For optimal safety, avoiding grapefruit products within 48 hours before or after taking Nifedipine is essential to prevent elevated active drug levels in the bloodstream. Pharmacists need to inform patients about this potentially serious interaction.

Drug interactions extend further to other medications as well. Co-prescribing Nifedipine with beta-blockers can lead to reduced heart rate and aggravated hypotension. This is particularly critical for older adults or those with multiple health issues, as they need careful monitoring of heart rates and blood pressure to avoid adverse effects.

Utilising electronic health records and e-health systems provides pharmacists with better access to a patient's medication history. This capability is invaluable for spotting potential interactions and communicating necessary adjustments or drug alternatives effectively.

During consultations, effective communication can significantly lower the risk of complications and enhance patient care and experience. Ensuring that patients are well-informed and aware of the risks associated with Nifedipine can make a considerable difference in their treatment outcomes.

Delivery Information for Addos XR Availability

City	Region	Delivery Time
Sydney	New South Wales	5–7 days
Melbourne	Victoria	5–7 days
Brisbane	Queensland	5–7 days
Perth	Western Australia	5–7 days
Adelaide	South Australia	5–7 days
Gold Coast	Queensland	5–9 days
Newcastle	New South Wales	5–9 days
Canberra	Australian Capital Territory	5–7 days
Hobart	Tasmania	5–9 days
Cairns	Queensland	5–9 days
Geelong	Victoria	5–9 days
Townsville	Queensland	5–9 days